These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1969668)

  • 41. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain.
    Kanba S; Yagi G; Oguchi E; Nakaki T; Kato R; Richelson E
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):133-4. PubMed ID: 1684393
    [No Abstract]   [Full Text] [Related]  

  • 42. The significance of the D2 dopamine receptor in schizophrenia as studied with PET.
    Wiesel FA
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():460A-461A. PubMed ID: 1354050
    [No Abstract]   [Full Text] [Related]  

  • 43. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment.
    Buckland PR; O'Donovan MC; McGuffin P
    Psychopharmacology (Berl); 1992; 106(4):479-83. PubMed ID: 1349752
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The inhibition of dopamine D1 and D2 receptors in human putamen by antipsychotic drugs].
    Kobayashi T; Shimizu H; Toru M
    Yakubutsu Seishin Kodo; 1990 Jun; 10(2):331-4. PubMed ID: 1979198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Climbing and stereotyped behaviours in mice require the stimulation of D-1 dopamine receptors.
    Vasse M; Chagraoui A; Protais P
    Eur J Pharmacol; 1988 Mar; 148(2):221-9. PubMed ID: 2897924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Catecholamine reward pathways and schizophrenia: the mechanism of the antipsychotic effect and the site of the primary disturbance.
    Crow TJ
    Fed Proc; 1979 Oct; 38(11):2462-7. PubMed ID: 39790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroleptic malignant syndrome.
    Pearlman C
    J Clin Psychopharmacol; 1992 Apr; 12(2):144. PubMed ID: 1349308
    [No Abstract]   [Full Text] [Related]  

  • 49. Chronic neuroleptic treatment and dopamine receptor regulation.
    Creese I; Snyder SH
    Adv Biochem Psychopharmacol; 1980; 24():89-94. PubMed ID: 6105809
    [No Abstract]   [Full Text] [Related]  

  • 50. Gamma-type endorphins and brain dopaminergic systems.
    van Ree JM; Elands J; Kiraly I; Wolterink G
    Prog Clin Biol Res; 1990; 328():287-90. PubMed ID: 1968266
    [No Abstract]   [Full Text] [Related]  

  • 51. [Role of dopamine receptors in the mechanism of action of neuroleptics].
    Lavretskaia EF; Kats MM; Baldenkov GN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):431-5. PubMed ID: 2859724
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Age-related changes in the regulation of behavior by D-1:D-2 dopamine receptor interactions.
    Murray AM; Waddington JL
    Neurobiol Aging; 1991; 12(5):431-5. PubMed ID: 1837593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroleptic-induced catalepsy: a D2 blockade phenomenon?
    Klemm WR
    Pharmacol Biochem Behav; 1985 Dec; 23(6):911-5. PubMed ID: 2867564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional interactive effects of D1 and D2 dopamine receptor blockade.
    Salama AI; Saller CF
    Adv Exp Med Biol; 1986; 204():137-50. PubMed ID: 2947425
    [No Abstract]   [Full Text] [Related]  

  • 55. Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure.
    Schmidt MH; Lee T
    Psychiatry Res; 1991 Mar; 36(3):319-28. PubMed ID: 1676523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blockade of both D1- and D2-dopamine receptors inhibits amphetamine-induced ascorbate release in the neostriatum.
    Oh C; Gardiner TW; Rebec GV
    Brain Res; 1989 Feb; 480(1-2):184-9. PubMed ID: 2565749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioural indices.
    Murray AM; Waddington JL
    Eur J Pharmacol; 1990 Sep; 186(1):79-86. PubMed ID: 2149339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple dopamine receptors and their implications in medicine.
    Kebabian JW
    Curr Opin Neurol Neurosurg; 1992 Aug; 5(4):514-8. PubMed ID: 1387567
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
    See RE; Aravagiri M; Ellison GD
    Life Sci; 1989; 44(3):229-36. PubMed ID: 2536879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.